



August 7, 2017

## **TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update**

### **Investor Conference Call to be held Wednesday, August 9, 2017 at 8:30am ET**

NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Wednesday August 9, 2017 at 8:30am ET to discuss results for the second quarter of 2017 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter 2017 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com). An audio recording of the conference call will also be available for replay at [www.tgtherapeutics.com](http://www.tgtherapeutics.com), for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

TGTX-G

Contact

Jenna Bosco

Vice President, Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

 [Primary Logo](#)

Source: TG Therapeutics, Inc.

News Provided by Acquire Media